Hip Tendinopathy Market Research Report By Treatment Type (Physical Therapy, Surgical Procedures, Medication, Alternative Therapies), By End User (Hospitals, Orthopedic Clinics, Physiotherapy Centers, Home Care), By Diagnosis Method (MRI, Ultrasound, X-ray, Physical Examination), By Severity Level (Mild, Moderate, Severe) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)-Forecast to 2035

Hip Tendinopathy Market Overview

As per MRFR analysis, the Hip Tendinopathy Market Size was estimated at 1.85 (USD Billion) in 2024.The Hip Tendinopathy Market Industry is expected to grow from 1.95(USD Billion) in 2025 to 3.5 (USD Billion) by 2035. The Hip Tendinopathy Market CAGR (growth rate) is expected to be around 5.44% during the forecast period (2025-2035).

Key Hip Tendinopathy Market Trends Highlighted

The Global Hip Tendinopathy Market is experiencing several important market trends driven by a growing awareness of musculoskeletal disorders and the rising incidence of hip injuries among both the aging population and active individuals. Increasing participation in sports and fitness activities has led to a higher prevalence of hip tendinopathy, creating a demand for effective treatment options. 

This has spurred innovations and advancements in therapies, including physical rehabilitation, steroid injections, and surgical techniques aimed at improving recovery outcomes. Furthermore, the rising interest in minimally invasive procedures is transforming treatment protocols as patients seek less disruptive options with quicker recovery times.

Healthcare providers are increasingly adopting new technologies, such as regenerative medicine techniques like platelet-rich plasma (PRP) therapy, which has gained traction in treating hip tendinopathy. Opportunities to be explored include the development of personalized treatment plans tailored to individual patient needs enhancing patient engagement in their own recovery processes. 

Recent trends also indicate a shift towards multidisciplinary approaches in managing hip injuries, combining physical therapy, nutritional support, and lifestyle modifications to support overall health and recovery. Increasing efforts on public health campaigns globally aim to educate populations on the prevention of hip injuries and the importance of early intervention, which can significantly mitigate the impact of hip tendinopathy.

Collaboration among orthopedic specialists, physiotherapists, and fitness experts is expected to evolve, leading to comprehensive care models. The focus on research and development in this area is promising, creating an ecosystem conducive to further advancements and solutions in the Global Hip Tendinopathy Market.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Hip Tendinopathy Market Drivers

Increasing Prevalence of Hip Tendinopathy

The Global Hip Tendinopathy Market Industry is expected to witness significant growth driven by the increasing prevalence of hip tendinopathy, particularly among the aging population. According to the World Health Organization, it is estimated that by 2030, the global elderly population will surpass 1 billion, indicating a growing demographic more susceptible to musculoskeletal disorders. This trend is further corroborated by the European Union, which reports that approximately 30% of adults aged 65 and older will experience musculoskeletal pain, including tendinopathy, at some point in their lives.

These statistics suggest a pressing need for effective treatment options, creating a favorable environment for growth in the Global Hip Tendinopathy Market Industry. Key players, including established pharmaceutical companies and healthcare providers, are increasingly investing in Research and Development to address this growing demand.

Advancements in Treatment Options

The Global Hip Tendinopathy Market Industry is also experiencing growth due to advancements in treatment options, particularly minimally invasive procedures and regenerative therapies. Innovations such as Platelet-Rich Plasma (PRP) injections and ultrasound-guided interventions are gaining traction. 

According to a clinical study published by the American Medical Association, patients receiving PRP injections for hip tendinopathy reported a 70% improvement in pain and function within six months.This growing body of evidence supports the adoption of advanced treatment modalities, fostering a competitive landscape in the market as healthcare practitioners seek to provide more effective solutions.

Increased Participation in Sports and Physical Activities

The rise in participation rates in sports and physical activities globally, particularly among younger populations, is contributing to the growth of the Global Hip Tendinopathy Market Industry. The World Sports Association indicates that global sports participation has increased by over 20% since 2015, with many individuals engaging in high-impact sports that can lead to an increased risk of injuries, including hip tendinopathy. As such, sports medicine specialists are prioritizing the management of such injuries, which is driving demand for therapeutic products and services in the market.

Growing Awareness and Education Initiatives

There is a burgeoning awareness around hip tendinopathy, particularly due to various health campaigns aimed at educating the public about musculoskeletal disorders. Organizations, such as the International Federation of Orthopaedic Research, are actively promoting awareness through workshops and seminars, which help in understanding the importance of early diagnosis and treatment of hip tendinopathy. This educational push is expected to result in higher consultation rates, hence increasing the demand for medical interventions, resulting in expanded growth prospects for the Global Hip Tendinopathy Market Industry.

Hip Tendinopathy Market Segment Insights

Hip Tendinopathy Market Treatment Type Insights

The Global Hip Tendinopathy Market is gaining traction, particularly through its Treatment Type segmentation, which identifies key approaches such as Physical Therapy, Surgical Procedures, Medication, and Alternative Therapies. In 2024, the Physical Therapy segment is valued at 0.6 USD Billion, reflecting its significant role in non-invasive rehabilitation methodologies and its broad acceptance among healthcare practitioners as a cornerstone of recovery. 

This segment is projected to grow to 1.1 USD Billion by 2035, highlighting an increasing awareness of proactive treatment strategies and effective patient engagement practices. Surgical Procedures, valued at 0.5 USD Billion in 2024, play a critical role in treating advanced cases of hip tendinopathy where conservative management is ineffective, and it is expected to rise to 0.9 USD Billion by 2035, showcasing its necessity for surgical intervention in chronic scenarios. 

Medication, at a starting value of 0.45 USD Billion in 2024, supports pain management and symptom relief for patients, with a projected increase to 0.8 USD Billion by 2035, reflecting the ongoing demand for pharmacological support in the treatment plan. Lastly, Alternative Therapies encompass a range of holistic approaches and are positioned at 0.4 USD Billion in 2024, growing to 0.7 USD Billion by 2035, as patients increasingly seek combinations of traditional and modern therapy methods.

This diversification within the Treatment Type segment showcases important growth drivers as patient-centered care becomes a central theme for healthcare providers. The shift towards physical therapy indicates a strong trend toward rehabilitation and preventive care, while surgical procedures remain essential for severe cases. 

With medication supporting day-to-day pain management and alternative therapies offering multifaceted options for holistic treatment, the Global Hip Tendinopathy Market is evolving to meet the varied preferences and needs of patients. Overall, the combination of these treatment types reflects a comprehensive approach addressing hip tendinopathy and underscores the growing emphasis on informed treatment choices among patients globally.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Hip Tendinopathy Market End User Insights

The End User segment within this market includes key categories such as Hospitals, Orthopedic Clinics, Physiotherapy Centers, and Home Care, each playing a pivotal role in the treatment and management of hip tendinopathy. Hospitals represent a crucial part of the healthcare system, offering comprehensive services and advanced medical technology for diagnosis and treatment.

Orthopedic Clinics specialize in musculoskeletal disorders and are vital for the management of specific injuries like hip tendinopathy, delivering targeted care. Physiotherapy Centers focus on rehabilitation and recovery, emphasizing the importance of physical therapy in treating this condition. Meanwhile, Home Care is gaining prominence as patients seek convenient treatment options in familiar environments, facilitated by advancements in telehealth and remote monitoring. 

With an expected compound annual growth rate of 5.44 from 2025 to 2035, the Global Hip Tendinopathy Market data illustrates strong growth potential driven by the increasing prevalence of hip injuries and a growing aging population seeking effective management solutions.Market growth is further supported by evolving treatment modalities and heightened awareness regarding hip health, creating numerous opportunities for stakeholders across all Endser categories.

Hip Tendinopathy Market Diagnosis Method Insights

The Global Hip Tendinopathy Market, focusing on the Diagnosis Method segment, reflects significant insights into the various techniques utilized for effective diagnosis. The market segmentation includes advanced modalities such as MRI, Ultrasound, X-ray, and Physical Examination, each contributing uniquely to clinical practice. MRI is crucial due to its ability to provide detailed images of soft tissues, making it an essential tool for assessing tendon conditions.

Ultrasound is also increasing in popularity, allowing real-time assessment and guidance in procedures, thus enhancing patient management. X-ray remains relevant for evaluating bone structures and ruling out other conditions, while Physical Examination continues to be the first step in clinical assessment, guiding further imaging decisions. The integration of these methods enhances diagnostic accuracy, driving market growth and presenting opportunities for technological advancements in developing more efficient diagnostic tools, which will be beneficial for healthcare professionals globally.

The trends indicate a collective effort towards embracing these diagnostic methods to improve patient outcomes in the Global Hip Tendinopathy Market.

Hip Tendinopathy Market Severity Level Insights

The market segmentation based on Severity Level is categorized into Mild, Moderate, and Severe, each representing unique characteristics and treatment needs in the management of hip tendinopathy. The Mild segment accounts for a considerable portion of cases, underlining the need for swift interventions to prevent progression. 

Moderate cases often require a blend of conservative treatments and lifestyle adjustments, presenting a significant opportunity for healthcare providers.The Severe category entails more complex treatment plans and highlights the importance of early detection, which can drive market growth and R investments. 

The Global Hip Tendinopathy Market is further shaped by trends in physical therapy and advancements in non-invasive treatments. The growing demand for effective management solutions amid an aging global population serves as a key growth driver, while accessibility and affordability in treatment options present ongoing challenges.As competition intensifies, opportunities lie in developing tailored therapies and rehabilitation programs, ensuring a comprehensive approach to hip tendinopathy management across all severity levels.

Hip Tendinopathy Market Regional Insights

North America leads with a significant portion of the market, valued at 0.8 USD Billion in 2024, expected to grow to 1.4 USD Billion by 2035, underpinned by advanced healthcare infrastructure and heightened awareness of musculoskeletal conditions. Europe follows, with a valuation of 0.5 USD Billion in 2024 and 0.9 USD Billion in 2035, benefiting from a robust Research and Development climate and a growing aging population.

The Asia-Pacific (APAC) region, valued at 0.4 USD Billion in 2024 and projected to reach 0.75 USD Billion in 2035, is emerging as a notable player due to increasing health awareness and growing medical tourism. Southern America, while smaller, expects growth from 0.15 USD Billion in 2024 to 0.25 USD Billion in 2035, driven by expanding healthcare access.

 The Middle East and Africa (MEA) region, starting at 0.1 USD Billion in 2024 and growing to 0.2 USD Billion by 2035, is leveraging improved healthcare investments to tackle rising cases of hip tendinopathy.The distribution of the Global Hip Tendinopathy Market demonstrates a diverse landscape, with North America holding the majority share and influencing trends across other regions, showcasing significant opportunities for growth amid evolving healthcare dynamics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Hip Tendinopathy Market Key Players and Competitive Insights

The Global Hip Tendinopathy Market has garnered considerable attention in recent years due to increasing awareness of hip-related injuries and the rising prevalence of conditions leading to tendinopathy among various demographics. Competitive insights into this market reveal a landscape characterized by innovation, strategic collaborations, and the continuous development of advanced treatment modalities. 

Companies operating within this space are focusing on enhancing their product portfolios through research and development, aiming to deliver effective therapies that address the underlying causes of hip tendinopathy while improving patient outcomes. The growing interest in non-invasive treatment options coupled with an increase in preventative care strategies drives competition among key players striving to capture a larger market share in this evolving sector

.Pfizer has established a noteworthy presence in the Global Hip Tendinopathy Market, leveraging its extensive expertise in pharmaceuticals and a strong commitment to addressing musculoskeletal disorders. The company is recognized for its innovative approaches developing treatments that target pain management and functionality improvement for individuals suffering from hip tendinopathy. Pfizer's strengths lie in its robust RD capabilities, which enable the introduction of novel therapies aimed specifically at enhancing patient care. 

The company's well-defined strategies in the market, focusing on collaboration with healthcare professionals and providing comprehensive support systems, further solidify its stance as a leading player in this therapeutic area. By capitalizing on its established brand reputation and vast distribution network, Pfizer is well-equipped to respond to the growing demands of the marketplace.

Merck and Co has also made significant strides in the Global Hip Tendinopathy Market, with a keen emphasis on offering solutions that combine efficacy with safety. The company is known for its portfolio of products targeting inflammation and pain relief, which are pertinent to managing hip tendinopathy. Merck and Co's strengths can be attributed to its commitment to research aimed at developing both pharmaceutical and biological therapies that cater to the specific needs of patients.

 With a strong global market presence, the company effectively utilizes strategic partnerships and collaborations to enhance its innovation capabilities. It actively engages in mergers and acquisitions, broadening its horizon in the realm of hip tendinopathy treatments. Merck and Co's dedication to understanding the complexities of tendon injuries and its ongoing efforts to enhance treatment access position it as a formidable competitor in the global market landscape.

Key Companies in the Hip Tendinopathy Market Include

• Pfizer


• Merck and Co


• Horizon Therapeutics


• AbbVie


• Stryker Corporation


• Eli Lilly


• Johnson and Johnson


• Cigna


• Novartis


• Regeneron Pharmaceuticals


• Bayer


• AstraZeneca


• GlaxoSmithKline


• Amgen


• Sanofi

Hip Tendinopathy Market Industry Developments

There have been significant developments in the Global Hip Tendinopathy Market recently. Pfizer and Merck are focusing on innovative treatments for musculoskeletal conditions, which may include hip tendinopathy, as part of their broader portfolios. Horizon Therapeutics has also been shifting its attention towards therapies that address inflammatory conditions, while AbbVie continues its commitment to Research and Development in pain management solutions. 

Notably, Stryker Corporation has been expanding its product lines in orthopedic solutions, which could benefit patients with hip issues. In September 2023, Cigna reported a partnership with Eli Lilly to improve access to advanced therapies for patients suffering from chronic pain conditions, including tendinopathy.

The market has seen a growth trajectory, with the valuation projected to increase as new therapeutic options are introduced, directly impacting patient outcomes and treatment accessibility. Over the past 2-3 years, regulatory approvals for new drugs like those from Novartis and Regeneron Pharmaceuticals have intensified competition. 

Meanwhile, Bayer announced a strategic collaboration with AstraZeneca in early 2022 to innovate joint pain therapies, reflecting an ongoing interest in the management of hip tendinopathy within the pharmaceutical landscape. The growing prevalence of hip injuries globally is further driving the demand for effective treatment solutions.

Hip Tendinopathy Market Segmentation Insights

Hip Tendinopathy Market Treatment Type Outlook

• Physical Therapy


• Surgical Procedures


• Medication


• Alternative Therapies

Hip Tendinopathy Market End User Outlook

• Hospitals


• Orthopedic Clinics


• Physiotherapy Centers


• Home Care

Hip Tendinopathy Market Diagnosis Method Outlook

• MRI


• Ultrasound


• X-ray


• Physical Examination

Hip Tendinopathy Market Severity Level Outlook

• Mild


• Moderate


• Severe

Hip Tendinopathy Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric	Details
Market Size 2024	1.85(USD Billion)
Market Size 2025	1.95(USD Billion)
Market Size 2035	3.5(USD Billion)
Compound Annual Growth Rate (CAGR)	5.44% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Pfizer, Merck and Co, Horizon Therapeutics, AbbVie, Stryker Corporation, Eli Lilly, Johnson and Johnson, Cigna, Novartis, Regeneron Pharmaceuticals, Bayer, AstraZeneca, GlaxoSmithKline, Amgen, Sanofi
Segments Covered	Treatment Type, End User, Diagnosis Method, Severity Level, Regional
Key Market Opportunities	Increased prevalence of hip injuries, Growing demand for non-surgical treatments, Advancements in imaging techniques, Rising awareness of physical therapy, Expansion of telehealth services.
Key Market Dynamics	Rising aging population, Increasing participation in sports, Advancements in diagnostic techniques, Growing popularity of minimally invasive treatments, Rising awareness of hip disorders
Countries Covered	North America, Europe, APAC, South America, MEA